New pill could ease stiffness and pain for ankylosing spondylitis patients
NCT ID NCT07172360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether VC005 tablets can reduce symptoms of active ankylosing spondylitis, a type of arthritis that mainly affects the spine. About 420 adults aged 18 to 70 will receive either VC005 or a placebo for 48 weeks. The main goal is to see how many achieve a 20% improvement in disease activity after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VC005 tablets
What this could lead to
If successful, this could provide a new oral treatment option to control symptoms and slow disease progression in people with active ankylosing spondylitis.
What could go wrong
This is still an experimental drug. Phase 3 trials can fail to show enough benefit or reveal unexpected side effects. The results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••